Cancer Seminar Series
Join us for this interdisciplinary seminar series highlighting cutting edge clinical, translational, and basic research topics in cancer from our research partner institutes: UQ Diamantina, QUT and the Mater. Focussing primarily on communicating the findings of early-to-mid career researchers, new faculty members along with notable guest speakers, this seminar series serves as an important tool to promote discussion and collaboration.
- Dr Jatin Patel
- Dr Jenni Gunter
- Dr Mark Adams
- Dr Yaowu He
- Promote researchers
- Encourage discussion
- Enable collaboration
- Share techniques
| Seminar Details | Speaker | Title | Speaker Bio |
|
Date: Thursday 5 March Seminar: 9am-10am Venue: Seminar Room 2003 |
Professor John Hooper (Mater Research Institute) | Standing on the outside looking in - models and molecular targets for advanced ovarian and pancreactic cancer |
John Hooper leads the Cancer Biology Laboratory at the Mater Research Institute UQ. His research focus is on cancers of the ovary, pancreas, prostate and bowel, studying the molecular drivers of these malignancies and pre-clinical testing of new diagnostic/predictive tools and drug leads. His laboratory works closely with clinical teams involved in the care of cancer patients, and with companies engaged in the translation of biomedical discoveries for clinical use. |
|
Date: Thursday 5 March Seminar: 9am-10am Venue: Seminar Room 2003 |
Dr. Brittney Harrington (NIH, Maryland) |
Drugs targeting ovarian cancer tumour-initiating cells enhance oxidative stress and prevent disease recurrence |
Dr. Brittney Harrington is a Postdoctoral Fellow performing translational research at the National Cancer Institute of the National Institutes of Health in Maryland, USA. Dr. Harrington completed her undergraduate and postgraduate studies at the University of Queensland, and Mater Research Institute in Brisbane, Australia. Dr. Harrington's research is focused on the discovery of new targeted therapies for ovarian cancer and using clinically relevant models of the disease. |
|
Date: Tuesday 20 February Seminar: 9am-10am Venue: Seminar Room 2003 |
Dr Pascal Dujf | Chromosome arm aneuploidies shape tumour evolution and drug response |
Dr Pascal Duijf obtained a Bachelor's degree in Biology and a Master's degree in Medical Biology from the Radboud University Nijmegen in the Netherlands and was awarded two scholarships that enabled him to gain research experience in cell biology at Harvard Medical School in Boston, MA in the United States. His research focuses on identifying the causes and consequences of genomic instability in the development of cancer (see also 'Research Interests' below for more details). He aims to translate this knowledge into the development of cancer diagnostic, therapeutic and precision medicine approaches. To achieve this, he uses a broad range of methods, including mouse modelling, genome editing, microscopy, cell and molecular biology, molecular pathology, proteomics and computational systems genomics. |
2018 SCHEDULE
| Date | Speakers | Title |
| 22/02/2018 | Dr. Jatin Patel (UQDI) | Endovascular progenitors initiate and drive de novo vascularisation in melanoma |
| Dr. Nathalie Bock (QUT) | An in vitro bioengineered bone model to study the effects of androgen deprivation in the bone metastatic microenvironment of prostate cancer | |
| 08/03/2018 | TBC | TBC |
| Abdullah Al Emran (Dermatology Research Centre, UQDI) | Commonly integrated epigenetic modifications of differentially expressed genes lead to acquired drug resistance in cancer | |
| 22/08/2018 | Cancelled | |
| 05/04/2018 | Prof. Amanda Spurdle (QIMR) | Clinical classification of genetic variants: Research informing practice |
| 19/04/2018 | Prof. Nikolas Haass (UQDI) | RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes |
| Farhana Matin (QUT) | A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer | |
| 03/05/2018 | Dr. Chris Slape (UQDI) | EphA3: A new kind of oncogene |
| Dr. Mitchell Stark (Dermatology Research Centre, UQDI) | Whole exome analysis of naevi reveals mechanisms for development and maintenance of benign neoplasms | |
| 17/05/2018 | Dr. Rehan Villani (UQDI) | Deciphering the role of cancer-associated fibroblasts in basal cell carcinoma |
| Arutha Kulasinghe (QUT) | Circulating tumour cells: the "leukemic" phase of solid cancers | |
| 31/05/2018 | ||
| Dr. Dubravka Skalamera (MRI) | Using high-content time-lapse imaging to investigate effects of oncogenic mutations in melanocyte-keratinocyte-fibroblast interaction | |
| 14/06/2018 | Dr. Abu Sina (AIBN, UQ) | Interfacial Biosensing: A new avenue for sensing cancer biomarkers |
| 28/06/2018 | Dr. Kelly-Anne Masterman (MRI) | Harnessing CD141+ Dendritic Cells (DC) for immunotherapy |
| 12/07/2018 | Dr. Tracy O'Mara (QIMR) | TBC |
| 26/07/2018 | Cancelled due to TRI symposium | |
| 09/08/2018 | Prof. Glen Boyle (QIMR) (TRI auditorium) | Yin and Yang: Consequences of heterogeneous transcription factor expression in melanoma |
| 23/08/2018 | Dr. Samantha Stehbens (UQDI) | Microtubule-Dependent Mechanosensing in Cell Migration and Cancer Invasion |
| 06/09/2018 | Dr. Julia Pagan (UQ School of Biomed. Sc.) | Regulation of cellular pathways by SCF ubiquitin ligases |
| 20/09/2018 | Dr. Roberta Mazzieri | Resetting the Tumour Microenvironment to Improve cancer Immunotherapy |
| Dr Jay Gunawardana | Somatic IL4R Mutations in Primary Mediastinal B-cell Lymphoma | |
| 04/10/2018 | Dr. Daniel Kerage (UQDI) | TBC |
| 18/10/2018 | Dr. Shannon Joseph (UQDI) | EGFR trafficking distribution, therapeutic outcomes and therapeutic potential |
| Heinz Hammerlindl (Dermatology Research Centre, UQDI) | Characterisation of therapy induced cellular reprogramming identifies vulnerabilities during the development of drug resistance in BRAF mutant melanoma | |
| 15/11/2018 | Joachim Torrano (Dermatology Research Centre, UQDI) | The potential role of IFN-mediated H3K9me3 in therapy-induced reprogramming |
| Martin Sadowski (QUT) | Lipid uptake fuels the fury of prostate cancer | |
| 29/11/2018 | TBC | |
2017 SCHEDULE ARCHIVE
| Date | Speakers | Topic |
| 09/03/2017 | Dr. Yaowu He (Mater) | Functional importance of CDCP1 in colorectal cancer |
| Dr. Jatin Patel (UQDI) | Defining the vascular stem cell niche for cancer and tissue regeneration | |
| 23/03/2017 | Dr. Orla Gannon (UQDI) | Are pathogens associated with breast cancer? |
| Phoebe Sarkar (APCRC-Q) | Characterizing the role of insulin in advanced prostate cancer | |
| 06/04/2017 | Dr. Pascal Duijf (UQDI) | Pan-cancer analysis identifies novel features of chromosome arm-level somatic copy number aberrations |
| Chris Oh (IMB, UQ) | Epigenetic signalling of nuclear hormone receptor and cofactor in breast cancer | |
| 20/04/2017 | TBC | TBC |
| 04/05/2017 | Prof. Riccardo Dolcetti (UQDI) | Personalized immunotherapy to overcome tumour heterogeneity |
| 18/05/2107 | Abdullah Emran (UQDI / Dermatology Research Centre) | Distinct histone modifications define early drug resistance in cancer |
| Jana Panchadsaram (APCRC-Q) | The role of 5p15 locus in prostate cancer risk and progression | |
| 01/06/2017 | Dr. Kyle Upton (UQ School of Chemistry) | Mobile genetic elements in epithelial cancers |
| 15/06/2017 | Dr. Samantha Stehbens (UQDI) | Fibroblast Growth Factor Receptor 2 activating mutations Potentiate Migration and Invasion in Endometrial Cancer |
| Heinz Hammerlindl (UQDI / Dermatology Research Centre) | H3K4me3 remodelling drives acquired BRAF inhibitor resistance in melanoma | |
| 29/06/2017 | Kaylyn Tousignant (QUT) | Enhanced lipid uptake: a novel target to fight the adaptive response to androgen-targeted therapies in prostate cancer |
| Thomas Keech (Mater) | Bone marrow macrophages in acute myeloid leukaemia | |
| 13/07/2017 | Sharon Del Vecchio (UQDI, PAH) and Dr. Aaron Urquhart (Diagnostic Imaging, TRI) | Decoding the spectral fingerprint of kidney cancer |
| 27/07/2017 | Dr Honor Hugo (QUT) | Insight into mammographic density from human breast tissue cultivated ex vivo |
| Dr Ati Taherian Fard (APCRC-Q) | Temporal transcriptional dynamics of ZEB1-induced EMT in prostate cancer | |
| 10/08/2017 | Dr. Andreas Moeller (Head of Tumour Microenvironment, QIMR Berghofer) | Cancer-derived exosomes as new prognostic markers |
| 24/08/2017 | Dr. Stephen Mattarollo (UQDI) | Neuro-immuno-metabolic interactions in the tumour microenvironment |
| Scott Lovell (Visiting scholar, QUT) | Novel activity-based probes for the assessment of KLK activities in prostate cancer | |
| 07/09/2017 | Prof. Stacey Edwards (QIMR) | From GWAS to new drug targets for breast cancer |
| 21/09/2017 | Dr. Patricia Carreira Moreno (Mater) | Selection of a tumour-specific L1 insertion in the STC1 gene after chemotrherapy in an ovarian cancer patient |
| Farzana Ahmed (UQDI) | The role of MITF in melanoma tumour heterogeneity and drug resistance | |
| 05/10/2017 | Dr. James Wells (UQDI) | Rapamycin-induced reduction of de novo squamous cell carcinoma establishment - a role for CD8-T-cells? |
| 19/10/2017 | Dr. Shannon Joseph (UQDI) | Reversing resistance to monoclonal antibody therapy in metastatic Head and Neck Squamous Cell Carcinoma and triple negative breast cancers - CESTEM trial update |
| 02/11/2017 | Prof. Shubha Chiplunkar (Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India) | Gamma delta T cells and cancer immunotherapy |
| Rayzel Fernandes (Dame Roma Mitchell Cancer Research Labs, University of Adelaide) | miR-194 regulates androgen receptor signalling in prostate cancer | |
| 16/11/2017 | Dr. Abbas Shafiee (ihbi) | TBC |
| 22/11/2017 | Special Cancer-Immunology seminar: International speaker Professor Tetsuo Akimoto (National Cancer Center Hospital East, Japan) | Proton beam therapy: state-of-the-art technology to target cancer. Clinical outcomes and current status in Japan |
| 30/11/2017 | Dr. Loredana Spoerri (UQDI) | MITF regulates dynamic heterogeneity and structural integrity in melanoma |
2016 SCHEDULE ARCHIVE
| ate | Speakers | Topic |
| 14/04/2016 | Dr Peter Simpson | Invasive lobular carcinoma – a special type of breast cancer |
| 28/04/2016 | Dr Graham Leggat | Tissue-resident memory T cells in precancerous skin |
| Shiv Hiriyur Nagaraj | TBC | |
| 12/05/2016 | Dr Stephen Matarollo | Improving response to immunotherapy in blood cancers |
| Dr Daniela Loessner | Engineering of tumour microenvironments | |
| 26/05/2016 | Dr Mitch Starck | "Melanoma-microRNAs”: from novel disease biomarkers through to target gene identification and regulation. |
| 9/06/2016 | Dr James Wells | Understanding the involvement of CD8 T-cells in the control of cutaneous squamous cell carcinoma |
| Dr Yonghua Sheng | MUC13 Protects Colorectal Cancer Cells from Death by Activating the NF-κB Pathway and Is a Potential Therapeutic Target | |
| 23/06/2016 | Dr Aaron Smith | External Speaker (SBMS) Melanoma |
| 7/07/2016 | QUT Speaker | TBC |
| Mater Speaker | TBC | |
| 21/07/2016 | Dr Jatin Patel | Defining the vascular stem cell niche for cancer and tissue regeneration |
| 4/08/2016 | Dr Lynn Fink | Using the MLL Fusion Transcriptome for Diagnosis in Childhood Acute Myeloid Leukaemia |
| Dr Eloise Dray | Exploiting DNA repair defects in breast cancer | |
| 18/08/2016 | John Price | External Speaker: Victoria Uni |
| 1/09/2016 | Dr Alice Kamphorst | RESCUE OF EXHAUSTED CD8 T CELLS BY PD-1 TARGETED THERAPIES IS CD28-DEPENDENT |
| Mater | TBC | |
| 29/09/2016 | Dr Alok Shah | TBC |
| Thomas Kryza | TBC | |
| 13/10/2016 | Srividya Vaidyanathan | TBC |
| Vanessa Bonazzi | TBC | |
| 27/10/2016 | Dr Graeme Walker | External Speaker (QIMR) : Melanoma |
| 10/11/2016 | TBC | Mater |
| TBC | QUT | |
| 24/11/2016 | TBC | External Speaker |
| 8/12/2016 | Dr Loredana Spoerri | Melanoma |
| QUT | TBC |
